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STRUCTURED ABSTRACT 
AIMS 
Ischaemic heart disease is the reduction of myocardial blood flow, caused by epicardial and/or 
microvascular disease. Both are common and prognostically important conditions, with distinct 
guideline-indicated management. Fractional flow reserve (FFR) is the current gold-standard 
assessment of epicardial coronary disease, but is only a surrogate of flow and only predicts 
percentage flow changes. It cannot assess absolute (volumetric) flow or microvascular 
disease. The aim of this study was to develop and validate a novel method that predicts 
absolute coronary blood flow and microvascular resistance (MVR) in the catheter laboratory. 
METHODS AND RESULTS 
A computational fluid dynamics (CFD) model was used to predict absolute coronary flow 
(QCFD) and coronary microvascular resistance (MVR) using data from routine invasive 
angiography and pressure-wire assessment. QCFD was validated in an in vitro flow circuit which 
incorporated patient-specific, 3-D printed coronary arteries; and then in vivo, in patients with 
coronary disease. In vitro, QCFD agreed closely with the experimental flow over all flow rates 
(bias +2.08 mL/min; 95% CI (error range) -4.7 to +8.8 mL/min; R2=0.999, p<0.001; variability 
coefficient <1%). In vivo, QCFD and MVR were successfully computed in all 40 patients under 
baseline and hyperaemic conditions, from which coronary flow reserve (CFR) was also 
calculated. QCFD-derived CFR correlated closely with pressure-derived CFR (R2=0.92, 
P<0.001). This novel method was significantly more accurate than Doppler-wire-derived flow 
both in vitro (±6.7 vs ±34 mL/min) and in vivo (±0.9 vs ±24.4 mmHg). 
CONCLUSIONS 
Absolute coronary flow and MVR can be determined alongside FFR, in absolute units, 
during routine catheter laboratory assessment, without the need for additional catheters, 
wires or drug infusions. Using this novel method, epicardial and microvascular disease can 
be discriminated and quantified. This comprehensive coronary physiological assessment 
may enable a new level of patient stratification and management. 
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TRANSLATIONAL PERSPECTIVE 
Current pressure wire-based methods of assessing coronary disease cannot assess 
absolute flow or microvascular disease. Our novel QCFD method, using only angiography-
based CFD and a pressure wire, simultaneously measures FFR, absolute coronary blood 
flow rate, microvascular resistance and coronary flow reserve. QCFD is suitable for use in the 
catheter laboratory and requires no dedicated catheters, wires or infusions. QCFD measures 
blood flow and microvascular resistance in absolute units and allows microvascular and 
epicardial disease to be differentiated, quantified and separately assessed, with the potential 
to improve diagnostic accuracy and clinical management. 
 
ABBREVIATIONS 
3-D  Three dimensional  
APV  Average peak (Doppler) velocity 
CFD  Computational fluid dynamics 
CFR  Coronary flow reserve 
FFR  Fractional flow reserve 
LAD  Left anterior descending artery 
LCX  Left circumflex artery 
MVD  Microvascular dysfunction 
MVR  Microvascular resistance 
Pa  Proximal (aortic) pressure 
Pd  Distal pressure 
QCFD  Absolute (volumetric) coronary flow rate computed by the novel method 
QDop  Coronary flow derived from Doppler ultrasound measurements 
Qexp  Volumetric flow rate, experimentally calibrated  
RCA  Right coronary artery 
SR  Stenosis resistance  
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1. INTRODUCTION 
Ischaemic heart disease is caused by restricted coronary blood flow.  Thus, measurements of 
coronary blood flow would be helpful to guide clinical interventions in the catheter laboratory.  
Coronary flow however, is challenging to measure and there are no methods for measuring it 
in routine clinical use.  Conversely, measurement of intracoronary pressure is simple, accurate 
and reproducible.  Consequently, cardiologists use translesional pressure measurements as 
a proxy for changes in blood flow.  Examples include fractional flow reserve (FFR) and 
instantaneous wave-free ratio (iFR).  These pressure-derived, surrogate flow indices are used 
widely to estimate the blood flow reduction due to epicardial coronary disease, and guide the 
appropriateness of percutaneous coronary intervention (PCI).  Use of FFR and iFR to guide 
PCI has become established in routine interventional practice and, compared with traditional 
angiography, has improved clinical outcomes.1-3 
Such is the popularity and efficacy of these pressure-derived indices, that it is perhaps easy 
to overlook some limitations.  First, FFR and iFR focus exclusively on the epicardial arteries 
and they cannot discriminate, or quantify microvascular disease.  This is a significant limitation 
because coronary microvascular dysfunction (MVD) affects >50% of those assessed in the 
catheter laboratory, is prognostically important, is implicated in the 20% of patients persistent 
angina after revascularisation, affects women disproportionality, consumes excessive 
healthcare resources and responds to European Society of Cardiology (ESC) guideline-
indicated treatment.4-9  Yet, because it is overlooked by pressure-derived indices, MVD 
remains undiagnosed and untreated in many patients.9  Second, FFR and iFR predict a 
percentage flow restriction, but of an unknown value.  They do not measure the actual 
(absolute) flow reduction in mL/min.  Because relieving ischaemia is the main target for PCI,10, 
11
 the ability to measure flow reduction in absolute terms may be beneficial.  Unless absolute 
flow is measured, the true magnitude of the flow reduction cannot be known.  Whilst there may 
be a broad correlation between FFR and absolute flow restriction, knowing whether an FFR 
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 5 
of 0.80 represents a 20 or 120 mL/min reduction in coronary flow can only add value to the 
coronary physiological assessment. 
If both pressure and flow could be measured reliably and simply, a number of additional 
physiological parameters could be calculated using basic haemodynamic laws.  These include 
microvascular resistance, stenosis resistance and coronary flow reserve, all of which help to 
discriminate and independently assess microvascular and epicardial coronary disease, thus 
providing a comprehensive physiological assessment of the entire coronary circulation. 
To enable this µnext-level¶ of coronary physiological assessment, there is therefore, a need for 
a method that measures absolute coronary blood flow, in combination with intracoronary 
pressure, practical for routine use in the cardiac catheter laboratory.  The aim of this study 
was to develop and validate a novel computational fluid dynamics- (CFD) based method 
which, with a standard pressure wire, could assess absolute coronary blood flow, and all 
relevant coronary physiological indices, including microvascular resistance. 
 
2. METHODS 
This research was performed at the University of Sheffield and Sheffield Teaching Hospitals 
NHS Foundation Trust UK, conformed to the principles of the Declaration of Helsinki and was 
approved by the NHS Health Research Authority, Regional Ethics Committee. Participating 
patients provided informed consent. 
 
2.1 The Computational Model 
Model inputs were standard coronary angiographic (digital imaging and communications in 
medicine, DICOM) images and pressure data.  The principal model output was absolute 
coronary flow (QCFD) in mL/min.  Three-dimensional coronary anatomy was reconstructed 
within the virtuQ software from two, 2-'DQJLRJUDSKLFSURMHFWLRQVDFTXLUHGDSDUWGXULQJ
end diastole, producing an axisymmetric 3-D model.12, 13  Volume mesh was constructed with 
1.2-1.5M elements with internal tetrahedra and wall inflation layers.  Pressure boundary 
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 6 
conditions were applied at the inlet and outlet, matched to the invasively measured values.14  
CFD simulation was performed (ANSYS, PA, USA) on a Dell Precision T5600 computer (Intel 
Xeon E5 2650, 2GHz processor, 32GB RAM) to a residual target of 10-6.15  The arterial wall 
was considered rigid.  The QCFD method is outlined in Figure 1.  Using the hydraulic equivalent 
RI2KP¶VODZQCFD and pressure data were used to calculate coronary MVR, SR and CFR 
under baseline (BL) and hyperaemic (Hyp) conditions as follows: 
 
095  3G4&)' 
 
65  3D3G4&)'  
 
&)5  4&)'
+\S
4&)'%/
 
 
2.2 In Vitro Assessment  
QCFD accuracy was validated in an in vitro flow circuit outlined in Figure 2.  To provide realistic 
experimental conditions, patient-specific coronary arteries were 3-D printed.  Cases included 
LAD, RCA and LCX arteries.  Percentage diameter stenosis ranged from 46% to 72% and 
lengths ranged from 68 mm to 84 mm.  Case specific details of the individual models and of 
the 3-D printing protocol can be found in the supplementary material.  Flow rates were varied 
from 50 to 180 mL/min in 10 mL/min increments.  Assuming a baseline flow of 60 mL/min and 
a CFR of up to three (in the context of flow-limiting lesions), this reflects a broad physiological 
range from baseline through hyperaemic conditions. 
Proximal pressure (Pa) was measured using a TruWave Pressure Transducer (Edwards 
Lifesciences Corp, US) and distal pressure (Pd) with a Volcano Primewire (Philips Volcano, 
NL).  Experimental flow rate (QExp) was repeatedly calibrated (prior to every analysis) by 
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 7 
measuring the fluid volume draining into a flask in one minute.  Coronary models were run at 
all 14 flow rates. Each was repeated three times, with a mean result recorded. 420 analyses 
were performed in total.  The pressure gradient (Pa - Pd) was applied as a pressure boundary 
condition at the inlet with zero pressure at the outlet.  For Doppler analysis, an ultrafine nylon 
powder (Orgasol® Powders, Arkema Group, FR) was added to the blood-analogue fluid to 
mimic the ultrasonic back-scatter properties of erythrocytes16. Doppler flow velocity was 
measured with a Philips Volcano Doppler FloWire® (Philips Volcano, CA, USA).  The Doppler 
wire was positioned and manipulated until the optimal (most dense) Doppler signal was 
recorded.  QDop was calculated from Doppler flow average peak velocity (APV), assuming a 
parabolic laminar flow profile (APV = 2 ڄ mean velocity), by considering the luminal cross-
sectional area (V = Q / A), where A was known precisely from the print files.   
The primary outcome measure was the accuracy of computed flow rate, QCFD, compared with 
the calibrated experimental flow rate (QExp), over all flow rates, to assess accuracy.  
Physiological flows are typically laminar (Reynolds (Re) number <500) but the experimental 
protocol had potential to induce supra-physiological flow rates (180 mL/min through severe 
stenosis).17  We therefore also report accuracy for the subset of cases where Reynolds 
number (Re) is less than 500 (5H  ȡ9'ȝ  where V is the average velocity over the circular cross 
section at the location with minimum diameter (stenosis), D the diameter at this location and 
ȡ and ȝ the density and viscosity respectively). 
To investigate whether there was any additional value in terms of increased QCFD accuracy in 
simulating pulsatile flow we also ran all the models at all flow rates under both steady and 
pulsatile flow profiles and simulated likewise in the computational model. Mean Pa and Pd were 
applied for steady analysis, and transient Pa and Pd measurements (with transient analysis) 
for pulsatile.  Details regarding how flow pulsatility was imposed in the flow circuit can be found 
in the supplementary material. 
 
2.3 First-In-Man In Vivo Assessment 
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Angiographic and invasive pressure data were collected from a previously unstudied cohort 
of 40 patients with stable coronary artery disease.  Patients with history of coronary artery by-
pass surgery were excluded.  QCFD was computed using the computational model as described 
above under baseline and hyperaemic conditions with time averaged Pa and Pd applied as the 
inlet and outlet boundary conditions respectively measured simultaneously from the pressure 
wire and guide catheter.  MVR, SR and CFR were calculated using the equations above.  An 
independent operator repeated 24 QCFD, MVR and QCFD-derived CFR analyses to derive inter-
observer variability. A subset of 20 patients also underwent Doppler flow wire (FloWire®, 
Philips Volcano, NL) assessment, from which coronary flow (QDop) and CFR (4'RS+\S 4'RS%/ ) were 
derived.  Measurements were repeated three times and the mean value was recorded.  
Pressure-derived CFR (CFRP-D) was also calculated according to: 
&)53' ඥ3D3GK\SHUDHPLF ? 3D3GEDVHOLQH.  
CFRP-D is known to correlate closely with CFR.18  CFRP-D was therefore compared with CFR 
derived from the novel QCFD method (CFRQCFD) and that derived from Doppler (CFRDop).  We 
also compared the pressure drop computed by the computational model with flow applied as 
the inlet boundary condition using both QCFD and QDop. 
 
2.4 Statistical Analysis 
Unless stated otherwise. mean delta and standard deviation (SD) of the mean are presented.  
Agreement was assessed using Bland-Altman plots.  Bland-Altman limits of agreement (±1.96 
SD), which comprise 95% of all results, were used as the error range 19.  Reproducibility was 
assessed by calculating the coefficient of variation (CoV) as the ratio of the standard deviation 
and mean values of repeated samples.  Pearson coefficient (r) was used to calculate linear 
correlation and R2. Seventeen or more SDLUHGVDPSOHVZHUHUHTXLUHGWRGHWHFWUDW
significance and 0.90 power. Analysis was performed using SPSS (IBM Corp, US).  
 
3. RESULTS 
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3.1  Accuracy of steady CFD analysis  
In all cases, over all flow rates, the difference between steady and pulsatile flow was negligible 
(bias -0.2 mmHg SD 0.9 mmHg equating to <1 mL/min difference).  Given that steady CFD 
analysis, based on time-averaged pressure boundary conditions is considerably quicker and 
simpler to compute, we elected to use this model for the (in vivo) analysis. Further details of 
this analysis can be found in the supplementary material.  
3.2  In Vitro assessment: QCFD predicts absolute flow  
Analysis in the 3-D-printed coronary artery geometries revealed close agreement and 
correlation between QCFD and QExp (mean delta +2.08 mL/min, SD 3.45 mL/min, limits of 
agreement -4.7 to +8.8 mL/min, R2 0.999; p<0.001) (Figure 3 and 4).  QCFD results were 
reproducible over three repeated measurements and CFD analyses (CoV <1.0%).  When 
cases with Reynolds numbers >500 were excluded, accuracy improved (mean delta +0.31 
mL/min, SD 2.58 mL/min, limits of agreement -4.7 to +5.3 mL/min) (Figure 3).  Results for the 
individual models are provided in the supplementary material.  The mean CFD processing 
time for all analyses was 189 seconds which is tractable for on table clinical decision making. 
3.3  Accuracy of Doppler flow 
The coefficient of variability for Doppler flow (QDop) was 6.4% when the wire was positioned at 
the inlet, and 17.4% distal to the stenosis.  Accordingly, only inlet measurements were 
considered further.  Despite a strong correlation (R2 0.98; p<0.001), QDop underestimated QExp 
(mean delta -14.9 mL/min) and limits of agreement were wider than QCFD (-48.4 to +18.6 
mL/min) (Figure 3).  Accuracy of QDop was only improved slightly when cases with Re>500 
were excluded (mean delta -8.34 mL/min, limits of agreement -36.4 to +19.8 mL/min).  Thus, 
we conclude that in the in vitro assessment, the novel QCFD method demonstrated close 
agreement and correlation with the actual flow rate with high reproducibility.  QCFD was 
considerably more accurate and reproducible than the Doppler wire method.  
3.3  First-In-Man In Vivo Assessment of QCFD and MVR 
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Forty patients were studied during invasive coronary angiography.  Mean age was 65 (±6) 
years and 86% were male.  Medical history included hypertension in 63%, type 2 diabetes 
mellitus in 32% and treated dyslipidaemia in 65%.  13% were current smokers and 5% had 
experienced prior myocardial infarction.  The arteries studied were 29 LAD (72.5%), five LCX 
(12.5%), five RCA (12.5%) and one left main stem (2.5%).  Mean FFR was 0.78 (±0.12).  QCFD 
was successfully computed in all cases under baseline and hyperaemic conditions.  The mean 
baseline QCFD was 62.0 (±28) mL/min and mean hyperaemic QCFD was 92.4 (±46) mL/min.  
QCFD was used to additionally calculate coronary MVR, SR and CFR.  Between baseline and 
hyperaemia, there was a 46% reduction in coronary MVR (1.62 ±0.88 to 0.88 ±0.45 
mmHgڄsڄmL-1, P<0.001) and a 21% rise in SR (0.19±0.12 to 0.23±0.14 mmHgڄsڄmL-1, P<0.01).  
Mean CFRQCFD was 1.56 (±0.44).  Inter-observer variability for QCFD, MVR and QCFD-derived 
CFR was 10%, 11% and 6% respectively. 
3.4.  Accuracy in predicting pressure-derived CFR and reproducing the measured 
pressure gradient 
CFR derived from the novel method (CFRQCFD) correlated closely with pressure-derived CFR 
(CFRP-D) (R2 0.92, P<0.001).  CFRP-D systematically underestimated CFRQCFD (mean delta -
0.16 ±0.17).  The measured and computed physiological parameters of all 40 patients are 
reported in table 1.  Doppler assessment was attempted in a subset of 20 patients but signal 
quality was inadequate for CFR estimation in two cases (10%).  In the remaining 18, the 
correlation between CFR derived from QDop, (CFRDop) and CFRP-D. was weak (R2 0.32, P=0.1).  
Similar to CFRQCFD, CFRDop also overestimated CFRP-D (mean delta -0.35 ±0.46).  When the 
computational model was reversed to apply flow at the inlet, application of QCFD accurately 
predicted the invasively measured pressure gradients (bias -0.29, SD 0.46 mmHg, limits of 
agreement -1.19 to +0.61 mmHg) whereas QDop consistently underestimated the invasively 
measured pressure gradient (bias -8.93, SD 12.46 mmHg limits of agreement -33.35 to +15.49 
mmHg).  Unlike the in vitro experiments, this does not provide a rigorous validation of flow 
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results, but it does suggest that the QCFD method was reasonably accurate relative to Doppler.  
Figure 5 demonstrates a screenshot of a result within the virtuQ software environment.  
 
4. DISCUSSION 
In this study we have demonstrated that absolute coronary blood flow can be determined from 
data generated during standard angiography and pressure wire assessment.  In addition to 
absolute coronary flow, FFR MVR, SR and CFR can be determined simultaneously, providing 
a comprehensive physiological assessment of the key physiological parameters which 
characterise the entire coronary circulation.  Uniquely, the method does not require any 
dedicated hardware, infusions or interventional effort. The novel method was more accurate 
and reproducible than the Doppler wire technique.   
Indices of translesional pressure ratio like FFR and iFR are themselves methods for deriving 
flow from pressure, and are superior to angiography in determining physiological lesion 
significance.  However, flow is not measured, but inferred, based upon a number of 
assumptions.  These indices reflect percentage changes in flow, of an unknown value, relative 
to a hypothetical norm.  We propose there is value in understanding flow and flow reduction 
in absolute terms.  An FFR of 0.75 indicates a 25% reduction of flow in that artery, compared 
with the undiseased state.  Precisely how much blood flow this is cannot be known.  This may 
be an important limitation, because an FFR of 0.75 in a diagonal branch may represent just a 
few mL/min of flow reduction, whereas the same FFR in a proximal LAD may indicate well 
over 100 mL/min flow reduction.  Similarly, an FFR 0.78 in the diagonal branch might seem to 
mandate PCI, whereas an FFR of 0.82 in a proximal LAD would not, even if, in absolute terms, 
the LAD lesion is associated with a greater reduction in absolute myocardial blood flow.  The 
value of FFR is that it has allowed interventionists to begin to quantify blood flow reduction in 
the catheter laboratory, but the ability to accurately quantify coronary blood flow changes in 
absolute terms would enable a more refined and patient-specific approach to coronary 
physiological assessment and treatment decisions.  Without any additional equipment than it 
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takes to measure FFR, our novel computational method additionally reports (i) the flow 
reduction in absolute terms, (ii) the microvascular resistance, (iii) the stenosis resistance and 
(iv) the coronary flow reserve.  Thus, the new method does not compete with traditional 
parameters like FFR or iFR, but instead complements and augments them, providing a new 
level of coronary physiological information.  Our method took between seven and eight 
minutes to complete using our software; four to five minutes to reconstruct the arterial 
geometry and three to compute the physiology.  Speed of computation was not the focus of 
this study rather accuracy of the novel method.  We anticipate results can be achieved in less 
than five minutes with development of the user interface and accelerated CFD code. 
An important advantage of the novel method is that it provides detailed information regarding 
microvascular disease.  The importance of MVD is increasingly being recognised. The 
coronary microvasculature holds 90% of the total myocardial blood volume.20  MVD is 
implicated in angina with no obstructive coronary disease (ANOCA), also known as µsyndrome 
X¶ or microvascular angina, which can lead to ventricular dysfunction even in those with normal 
epicardial arteries.  A recent study demonstrated evidence of coronary MVD in 68% of those 
attending the catheter laboratory with chest pain with no obstructive coronary disease and 39-
53% of those with concomitant epicardial disease.21  MVD is of prognostic importance in acute 
myocardial infarction,22 myocardial infarction with no obstructive coronary artery disease 
(MINOCA),23 cardiomyopathy,24, 25 cardiac transplantation,26 and heart failure with preserved 
ejection fraction (HFpEF).27  A recent randomised controlled trial demonstrated that coronary 
MVD responds well to stratified medical therapy.9  It is also hypothesised that coronary MVD 
may help to explain excess symptoms, risk and MACE in women,28  and the roughly 20% rate 
of persistent angina despite epicardial revascularisation with PCI.29-31  Because routine 
invasive testing with angiography and pressure-derived FFR /iFR overlook the microvascular 
physiology, virtuQ may have a valuable role in providing the necessary additional parameters 
to better characterise coronary pathophysiology, improve diagnosis of MVD and better stratify 
treatment in these patients. 
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Because IHD results from a reduction in coronary blood flow, developing a method for 
measuring flow has been a scientific goal for many years.  Until recently, this has meant using 
Doppler ultrasound or thermodilution but these indirect measures have proved impractical, 
technically challenging and inaccurate and have not been adopted into routine practice.32-35  
The challenges of maintaining an optimum Doppler signal are well documented 36-38 and the 
drawbacks widely acknowledged, even by those who advocate incorporating flow into 
physiological coronary assessment.17, 38-40  Misalignment of the transducer may underestimate 
flow velocity.  This was observed in the current study despite painstaking positioning in vitro.  
Doppler signal is sensitive to small movements and artefact is common.36, 39  Whilst these 
errors may µFDQFHO RXW¶ LQ WKH FDOFXODWLRQ RI &)5 UDWLR RI WZR YHORFLWLHV LQGLFHV VXFKDV
hyperaemic stenosis resistance (HSR = Pd / Doppler velocity) are far more susceptible to 
these errors.  Kousera et al used CFD simulation to predict the pressure-flow relationship in 
patients with coronary disease17 but underestimated pressure drop, likely because of error in 
the Doppler measurements, upon which their model was critically dependent.  CFR is 
somewhat resistant to these errors if the magnitude of baseline and hyperaemic error remain 
unchanged.  Indices such as hyperaemic or baseline stenosis resistance (3Dି3G$39 ), hyperaemic 
myocardial resistance ( 3G$39) and index of myocardial resistance (3GāPHDQWUDQVLWWLPH) are far 
more susceptible to error in the Doppler- or thermodilution-derived flow estimation.  Recently, 
an improved thermodilution method has been introduced that uses a monorail infusion 
catheter and a thermo- and pressure-sensitive wire.41-43  This method can measure absolute 
flow and MVR but requires additional dedicated hardware, reports hyperaemic flow only at the 
catheter location and is associated with wider limits of agreement than the QCFD method (±61.0 
mL/min vs ±6.75 mL/min), although the authors acknowledge that the virtuQ method is at an 
earlier stage of development and testing.  We believe virtuQ to be the first non-Doppler and 
non-thermodilution invasive method for predicting coronary flow to be described. 
Pressure-derived CFR is known to correlate closely with CFR derived from absolute flow as 
originally demonstrated in a canine model by Akasaka et al.18  In this study, CFR derived from 
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QCFD correlated closely with pressure-derived CFR, suggesting QCFD was an accurate 
measure of absolute coronary flow.  While the correlation was strong, CFR derived from QCFD 
was consistently greater than pressure-derived CFR.  This is interesting and reassuring 
because the same observation was made by MacCarthy et al in their experiment comparing 
thermo- and Doppler-derived CFR to pressure-derived CFR.44  The discrepancy is explained 
by the fact that the calculation of pressure-derived CFR neglects frictional energy losses, 
which our method fully captures. 
Clinical data required for the virtuQ method are angiographic images and standard pressure-
wire measurements, methods with which interventionists are already routinely familiar.  
Standard pressure wires tend to have better handling characteristics than those with combined 
Doppler or thermosensitive transducers.  virtuQ requires no additional hardware, wires or 
infusions.  A comprehensive physiological and anatomical assessment is generated (FFR, 
QCFD, MVR, SR, and CFR) under baseline and hyperaemic conditions and this can be 
visualised in a user-friendly software environment.  Whereas existing techniques estimate 
surrogate markers of flow (e.g. velocity or mean transit time) and incorporate these into ratios 
or indices, virtuQ determines flow and resistance in absolute units. 
CFD modelling is increasingly being applied to cardiovascular medicine to characterise and 
predict human vascular pathophysiology which is poorly approximated by simpler fluid 
dynamic equations such as those of Bernoulli and Poiseuille.14, 44, 45  Perhaps the best example 
is virtual FFR (vFFR) computed from angiography.  The accuracy of any CFD model is critically 
dependent upon tuning parameters that represent the physiological conditions of an individual 
patient i.e. boundary conditions.46-48  When computing vFFR, the boundary conditions are 
unknown and assumptions have to be made.  This limits accuracy.  This is not a problem for 
virtuQ because the boundary conditions are known precisely in all cases.  Thus, assumptions 
and therefore error are reduced. 
4.1 Limitations 
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In the in vitro experiment, the 3-D printed coronary models were rigid.  The same is true of the 
computational model.  However, we expect the overall effect coronary compliance to be 
negligible, especially in the context of a steady flow simulation and diseased vessels.  
Furthermore, previous CFD modelling work suggests a rigid assumption is acceptable in this 
context and does not adversely affect accuracy.14, 49-51  At the current stage of development, 
the model does not account for flow to side branches which underestimates flow in more 
proximal segments.  This is the opposite of the over-the-wire catheter infusion method 
because this predicts proximal but not distal flow.  Future work will improve this by quantifying 
the flow lost to proximal branches.  Because the simulation boundary conditions are known 
precisely, QCFD accuracy is dependent chiefly on the reconstruction protocol.  In this study, we 
evaluated Doppler, as a clinically approved comparator, and found it lacking; a similar 
evaluation of thermodilution derived markers of flow would also be valuable.42  A potential 
limitation of the QCFD method as a clinical tool is the requirement for a pressure gradient of at 
least 4 mmHg in the epicardial artery to drive the CFD simulation.  Theoretically, this means 
QCFD cannot be used in completely normal coronary arteries.  Assuming a mean arterial 
pressure of 90 mmHg, QCFD will be DFFXUDWHLQFDVHVZKHUH))5LVi.e. the majority of 
cases studied in the catheter laboratory.  This will affect baseline measurements more than 
hyperaemic.  Ideally, coronary flow would be interpreted in light of the mass of myocardium 
subtended by that artery.  However, there are currently no methods for measuring this in the 
cardiac catheter laboratory.  Non-invasive techniques such as PET or CMR may have a role, 
but are imprecise concerning the location of a stenosis. 
 
5. CONCLUSIONS 
Absolute coronary blood flow can be determined during standard angiography and pressure 
wire assessment.  This novel method provides a comprehensive coronary physiological 
assessment of flow, pressure and resistance, across the entire coronary circulation, without 
the need for additional hardware, catheters, wires, or infusions.  Using the novel method, 
epicardial and microvascular disease can be discriminated and quantified. 
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FIGURE LEGENDS 
 
Figure 1.  The computational method for computing absolute coronary blood flow.  
Coronary angiographic images are used to reconstruct the coronary anatomy.  Pressure 
data are used to tune boundary conditions.  CFD simulation computes the volumetric flow 
rate (QCFD) which enables coronary microvascular resistance (MVR), stenosis resistance 
(SR) and coronary flow reserve (CFR) to be calculated automatically. 
 
Figure 2.  The in vitro test-rig used for validating the method for determining absolute 
flow.  A gear pump (a) (TA Instruments, USA) delivered steady flow through the circuit.  In 
the pulsatile experiments, a pulsatile manifold (Bose Corp, USA) was used to deliver 
pulsatile flow.  Both devices were controlled by WinTest® software (Bose) (c).  A compliance 
chamber (d) was used in tandem with the pump and manifold to remove high frequency 
signal artefact. The blood analogue fluid (40/60 glycerol/water, viscosity 0.0035 Pa.s, 1082 
kg m-3 at room temperature)52 passed through the 3-D printed artery (e) reconstructed from 
patient data.  Clinical haemostatic valves were used to instrument the system with pressure 
and flow transducers through f.  The photographs demonstrate a 3-D printed artery within 
the circuit and the pressure wire tip can be seen on the zoomed image (g). The flow rate 
was regularly calibrated by measuring the volume of fluid draining into the reservoir chamber 
(not seen in this idealised diagram). 
 
Figure 3.  Bland-Altman plots demonstrating the accuracy of QCFD and QDop.  Panel A 
demonstrates the accuracy of the novel QCFD method over all flow rates (bias +2.08 mL/min; 
limits of agreement (±1.96 SD) ±6.75 mL/min).  Panel B demonstrates the accuracy of QCFD 
IRUFDVHVZLWK5HELDV+0.31 mL/min; limits of agreement ±5.0 mL/min).  Panel C 
demonstrates the accuracy of the Doppler method (QDop) over all flow rates (bias -14.9 
mL/min; limits of agreement ±33.5 mL/min).  Panel D demonstrates the accuracy of the 
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'RSSOHUPHWKRGIRUFDVHVZLWK5H (bias -8.34 mL/min; limits of agreement ±28.1 
mL/min).  The solid line indicates the bias (mean delta) and the broken lines indicate the 
limits of agreement (±1.96 SD).  Both methods were plotted against the gold-standard of the 
calibrated experimental flow rate (Qexp).  Note the difference in Y axis scale between the two 
methods. Each dot represents the average of three recordings i.e. 70 data points and 210 
samples. 
 
Figure 4.  Pressure gradient vs flow during in vitro testing for each of the five models 
over all flow rates.  There was close agreement between the experimental (gold-standard) 
flow (Qexp) indicated by the black line and the flow rate computed by the novel method (QCFD) 
indicated by the grey line (R2 0.999, p<0.001, E\3HDUVRQ¶VFRUUHODWLRQcoefficient).  The 
vertical dashed line represents the transition between physiological (Re < 500) and supra-
SK\VLRORJLFDO5HIORZUDWHV For Qexp, error bars represent the maximum and 
minimum values obtained from three measurements.  Because CFD results are inherently 
reproducible given identical setup parameters, error bars for the QCFD model were calculated 
from simulation data representing the influence of small errors in viscosity and density of the 
experimental blood analogue.  Each data point represents the mean of three repeated 
measurements i.e. 42 samples per model and 210 all together. 
 
Figure 5.  Example result from the virtuQ software graphical user interface. Absolute 
flow (mL/min), resting Pd/Pa, FFR, microvascular resistance (MVR), stenosis resistance 
(SR) and coronary flow reserve (CFR) are reported alongside the angiogram images (for 
reference), interactive 3-D reconstructed artery (physiologically colour mapped) and a 3-D 
vessel-sizing application to facilitate potential stent choice. The operator can select any two 
points within the vessel and the results update live. In this case, the FFR is negative, but 
flow, according to CFR, is borderline, likely due to the increased MVR.
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Case  Baseline  Hyperaemic  BL-Hyp % delta  CFR 
No Artery  Pa Pd dP Pd/Pa Q_CFD MVR SR  Pa Pd dP FFR Q_CFD MVR SR  MVR SR Q  Dop Q_CFD P-D 
1 LAD  88.0 79.4 8.7 0.90 22.7 3.49 0.38  78.0 61.0 17.0 0.78 35.8 1.70 0.47  -51 24 58  1.8 1.58 1.40 
2 LAD  92.7 85.6 7.1 0.92 67.7 1.26 0.10  75.7 61.5 14.2 0.81 109.2 0.56 0.13  -56 30 61  1.3 1.61 1.41 
3 RCA  106.3 99.6 6.7 0.94 89.8 1.11 0.08  83.5 71.3 12.2 0.85 165.3 0.43 0.07  -61 -13 84  2.1 1.84 1.35 
4 LAD  119.9 114.7 5.1 0.96 72.9 1.57 0.07  114.9 91.7 23.1 0.80 193.0 0.48 0.12  -69 71 165  2.4 2.65 2.13 
5 RCA  89.1 66.4 22.7 0.74 93.2 0.71 0.24  88.3 53.8 34.5 0.61 121.9 0.44 0.28  -38 17 31  1.5 1.31 1.23 
6 LCX  74.3 69.1 5.2 0.93 36.6 1.89 0.14  77.4 60.0 17.5 0.77 88.7 0.68 0.20  -64 43 142  1.1 2.42 1.83 
7 LAD  76.7 51.8 24.9 0.68 89.0 0.58 0.28  65.2 33.1 32.2 0.51 105.4 0.31 0.31  -47 11 19  1.1 1.19 1.14 
8 LAD  99.0 80.9 18.1 0.82 75.4 1.07 0.24  104.6 73.6 31.0 0.70 108.9 0.68 0.28  -36 17 44  1.5 1.44 1.31 
9 LAD  96.4 87.6 8.8 0.91 36.6 2.40 0.24  71.4 62.7 8.7 0.88 36.3 1.73 0.24  -28 0 -1  2.40 0.99 0.99 
10 LAD  117.3 112.9 4.4 0.96 23.5 4.80 0.19  102.3 89.0 13.3 0.87 52.8 1.69 0.25  -65 32 125  2.07 2.25 1.74 
11 RCA  90.0 88.0 1.9 0.98 41.3 2.13 0.05  75.0 67.6 7.4 0.90 102.5 0.66 0.07  -69 40 148  1.90 2.48 1.97 
12 RCA  112.1 59.4 52.7 0.53 115.1 0.52 0.46  118.8 62.2 56.5 0.52 119.7 0.52 0.47  0 2 4  1.18 1.04 1.04 
13 LAD  112.6 106.9 5.7 0.95 58.0 1.84 0.10  110.4 103.4 7.0 0.94 66.4 1.56 0.11  -15 10 14  1.38 1.14 1.11 
14 RCA  106.5 105.8 0.7 0.99 29.7 3.56 0.02  103.7 102.0 1.7 0.98 60.1 1.70 0.03  -52 50 102  2.42 2.02 1.56 
15 LAD  99.6 80.3 19.3 0.81 46.4 1.73 0.42  97.0 69.9 27.1 0.72 58.2 1.20 0.47  -31 12 25  1.61 1.25 1.18 
16 LAD  109.9 92.9 17 0.85 86.8 1.07 0.20  103.1 86.1 17.0 0.84 86.7 0.99 0.20  -7 0 0  1.67 1.00 1.00 
17 LAD  110.3 98.4 11.9 0.89 55.6 1.68 0.21  106.4 85.0 21.4 0.80 79.1 1.01 0.27  -40 29 42  1.2 1.42 1.34 
18 LCX  108.1 94.5 13.6 0.87 85.0 1.05 0.16  113.7 88.5 25.2 0.78 121.2 0.69 0.21  -34 31 43  2 1.43 1.36 
19 LAD  96.4 87.6 8.8 0.91 84.1 0.98 0.10  71.5 62.4 9.1 0.87 85.2 0.67 0.11  -32 10 1  F 1.01 1.02 
20 LAD  106.3 99.6 6.7 0.94 67.6 1.40 0.10  81.8 63.6 18.2 0.78 123.5 0.47 0.15  -66 50 83  F 1.83 1.65 
21 LAD  88.6 79.5 9.1 0.90 27.1 2.75 0.34  80.9 58.9 22.0 0.73 47.7 1.13 0.46  -59 35 76   1.76 1.55 
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22 LAD  74.4 49.5 24.9 0.67 56.2 0.83 0.44  65.0 32.9 32.1 0.51 65.8 0.43 0.49  -48 11 17   1.17 1.14 
23 LCX  73.6 68.3 5.3 0.93 38.7 1.64 0.14  79.1 60.8 18.3 0.77 81.6 0.68 0.22  -59 57 111   2.11 1.86 
24 LAD  96.3 87.5 8.8 0.91 41.0 2.01 0.21  71.5 62.4 9.1 0.87 41.1 1.40 0.22  -30 5 0   1.00 1.02 
25 LAD  99.0 80.9 18.1 0.82 57.4 1.32 0.32  104.4 73.5 30.9 0.70 79.8 0.86 0.39  -35 22 39   1.39 1.31 
26 LAD  119.0 112.1 6.9 0.94 42.0 2.55 0.16  103.4 88.5 14.9 0.86 62.6 1.33 0.24  -48 50 49   1.49 1.47 
27 LAD  112.3 106.7 5.6 0.95 61.5 1.65 0.09  122.0 113.1 8.9 0.93 82.2 1.32 0.11  -20 22 34   1.34 1.26 
28 LAD  99.6 80.3 19.3 0.81 47.3 1.59 0.41  95.5 68.7 26.8 0.72 58.8 1.09 0.46  -31 12 24   1.24 1.18 
29 LMS  78.8 64.7 14.1 0.82 169.4 0.35 0.08  75.3 47.4 27.9 0.63 257.4 0.16 0.11  -54 38 52   1.52 1.41 
30 LAD  87.0 82.1 4.9 0.94 43.4 1.78 0.11  84.1 70.9 13.2 0.84 79.5 0.83 0.17  -53 55 83   1.83 1.64 
31 LAD  81.5 73.0 8.5 0.90 44.1 1.54 0.19  78.3 58.2 20.1 0.74 78.2 0.68 0.26  -56 37 77   1.77 1.54 
32 LAD  101.6 84.4 17.2 0.83 38.2 2.08 0.45  82.5 48.2 34.3 0.58 59.7 0.72 0.57  -65 27 56   1.56 1.41 
33 LAD  93.5 86.3 7.2 0.92 79.4 0.97 0.12  87.0 62.0 25.0 0.71 148.7 0.38 0.17  -61 42 87   1.87 1.86 
34 LAD  109.0 102.0 7.0 0.94 52.4 1.85 0.13  118.8 110.2 8.6 0.93 59.0 1.78 0.15  -4 15 13   1.13 1.11 
35 LCX  130.4 119.4 11.0 0.92 79.6 1.44 0.14  118.0 101.0 17.0 0.86 105.2 0.91 0.16  -37 14 32   1.32 1.24 
36 LCX  94.2 84.9 9.3 0.90 83.4 0.96 0.11  96.7 67.6 29.1 0.70 173.8 0.36 0.17  -63 55 108   2.08 1.77 
37 LAD  99.7 90.5 9.2 0.91 75.1 1.14 0.12  98.2 84.8 13.4 0.86 92.5 0.86 0.14  -25 17 23   1.23 1.21 
38 LAD  88.0 82.6 5.4 0.94 66.8 1.16 0.08  78.7 58.6 20.1 0.74 138.1 0.39 0.15  -66 88 107   2.07 1.93 
39 LAD  67.1 59.8 7.3 0.89 50.4 1.09 0.14  69.8 59.4 10.4 0.85 63.7 0.85 0.16  -22 14 26   1.26 1.19 
40 LAD  69.8 64.4 5.4 0.92 49.7 1.20 0.11  66.0 56.1 9.9 0.85 73.9 0.69 0.13  -43 18 49   1.49 1.35 
 1 
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Table 1. Measured and computed physiological parameters for all 40 cases. LAD; left 
anterior descending, RCA; right coronary artery, LCX; left circumflex, LMS; left main stem, Pa; 
proximal pressure, Pd; distal pressure, Q_CFD; coronary flow computed by the novel method, 
MVR microvascular resistance, SR; stenosis resistance, FFR; fractional flow reserve, BL; 
baseline, Hyp; hyperaemia, CFR; coronary flow reserve, Dop; Doppler, P-D; pressure derived, 
F; failed 
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